Good_老虎社区_美港股上老虎

2021-07-21

Good

Moderna stock 'has taken on a life of its own' ahead of S&P 500 entrance<blockquote>Moderna 股票在标普500上市之前“有了自己的生命”</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":178413148,"tweetId":"178413148","gmtCreate":1626831384684,"gmtModify":1633770593282,"author":{"id":3583113201416266,"idStr":"3583113201416266","authorId":3583113201416266,"authorIdStr":"3583113201416266","name":"AliciaA","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Good</body></html>","htmlText":"<html><head></head><body>Good</body></html>","text":"Good","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/178413148","repostId":1120529749,"repostType":4,"repost":{"id":"1120529749","kind":"news","pubTimestamp":1626831113,"share":"https://www.laohu8.com/m/news/1120529749?lang=zh_CN&edition=full","pubTime":"2021-07-21 09:31","market":"us","language":"en","title":"Moderna stock 'has taken on a life of its own' ahead of S&P 500 entrance<blockquote>Moderna 股票在标普500上市之前“有了自己的生命”</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1120529749","media":"finance.yahoo","summary":"Moderna (MRNA) is set to join the S&P 500 index on Wednesday, replacing Alexion Pharmaceuticals Inc.","content":"Moderna (MRNA) is set to join the S&amp;P 500 index on Wednesday, replacing Alexion Pharmaceuticals Inc. (ALXN). The stock hassoaredamid the pandemic after its vaccine became instrumental in the fight against coronavirus.<blockquote>Moderna (MRNA) 将于周三加入标普500指数，取代 Alexion Pharmaceuticals Inc. (ALXN)。在其疫苗在抗击冠状病毒方面发挥作用后，该股在疫情大流行。</blockquote> Moderna stock has “taken on a life of its own,” Michael Yee, Managing Director and Senior Research Analyst at Jefferies, told Yahoo Finance (video above). “It's priced in a huge amount of assumptions over the next ten years that haven't played out yet. People believe it’s the Tesla of biotech.”<blockquote>杰富瑞（Jefferies）董事总经理兼高级研究分析师迈克尔-易（Michael Yee）告诉雅虎财经（上图视频），Moderna 的股票 “有了自己的生命”。“未来十年，它被大量的假设所定价，但这些假设尚未实现。人们认为这是生物技术的特斯拉”。</blockquote> That the biotech firm would be so well-recognized and valued at over $113 billion was no sure bet. For those who invested early in the company, that wager paid off.<blockquote>这家生物技术公司会如此广为人知，估值超过 1130 亿美元，这并不是一个确定的赌注。对于那些早期投资该公司的人来说，这一赌注得到了回报。</blockquote> \"Think about how fast they came up with nothing a year ago, and all of a sudden, they're doing $21 billion and have injected hundreds and hundreds and hundreds of millions of people with their drug safely,\" Yee said. \"That's a pretty big accomplishment.\"<blockquote>“想想一年前他们一无所获的速度有多快，突然之间，他们赚了 210 亿美元，并安全地为数亿人注射了药物，”易说。“这是一个相当大的成就。”</blockquote> <img src=\"https://static.tigerbbs.com/bb60075c3a90de67d77af15634fd41fa\" tg-width=\"858\" tg-height=\"588\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> Moderna's rise to recognition<blockquote>Moderna的崛起</blockquote> The Cambridge, Massachusetts-based biotech company was founded in 2010 and spent its first two years instealth modedeveloping drugs using messenger RNA (mRNA).<blockquote>这家总部位于马萨诸塞州剑桥的生物技术公司成立于 2010 年，前两年一直在使用信使 RNA (mRNA) 开发药物。</blockquote> The promise of mRNA — what Moderna calls \"the software of life\" — in pharmaceuticals has been huge. Modified mRNA teaches cells how to produce the proteins needed to fight and prevent infection. By altering the four letters in an mRNA sequence, this new class of drugs can, in theory, target a wide range of illnesses. The mRNA platform also promises to accelerate the time it takes to select, develop, and manufacture vaccines.<blockquote>mRNA——现代评级公司的“生命软件”——在制药领域的前景是巨大的。修饰的mRNA教会细胞如何产生对抗和预防感染所需的蛋白质。通过改变mRNA序列中的四个字母，这类新药理论上可以针对多种疾病。mRNA平台还有望加快选择、开发和制造疫苗所需的时间。</blockquote> On these high expectations, Moderna achieved a billion-dollar valuation within two years. Initially, the company focused its efforts on treatments for cancer, cardiovascular issues, and some rare diseases. However, developers were embattled with the problem of delivering mRNA to cells — too-strong doses set the body's immune system against the drug while too-weak doses proved ineffectual in fighting disease.<blockquote>在这些高期望下，Moderna在两年内实现了10亿美元的估值。最初，该公司将精力集中在癌症、心血管问题和一些罕见疾病的治疗上。然而，开发人员被将mRNA输送到细胞的问题所困扰——太强的剂量会使身体的免疫系统抵抗药物，而太弱的剂量被证明在对抗疾病方面无效。</blockquote> Over time, the company shifted to pursuing vaccines, which CEO Stéphane Bancel believed would demonstrate the viability of the technology. Moderna had nine vaccines that made it to clinical trials, although none achieved liftoff.<blockquote>随着时间的推移，该公司转向追求疫苗，首席执行官 Stéphane Bancel 认为这将证明该技术的可行性。Moderna 有九种疫苗进入临床试验，但没有一种成功。</blockquote> That changed when a deadly global pandemic hit, kicking off a vaccine race in the U.S. between Moderna and pharmaceutical titans like Pfizer (who also developed an mRNA vaccine in partnership with BioNTech) and Johnson &amp; Johnson.<blockquote>当致命的全球大流行袭击时，这种情况发生了变化，在美国引发了 Moderna 与辉瑞（辉瑞还与 BioNTech 合作开发了 mRNA 疫苗）和强生公司等制药巨头之间的疫苗竞赛。</blockquote> The company's decade of research iterating on the basic science behind mRNA proved consequential in its success in developing a coronavirus vaccine in record time. On January 11, 2020, Chinese scientists revealed the genetic sequence for SARS-CoV-2. By February 24, 2020, Moderna shipped thefirst dosesof its mRNA coronavirus vaccine to the NIAID to begin phase I trials. And in December of 2020, phase III trials demonstrated 94.1% efficacy against symptomatic COVID-19. The FDA subsequently approved Moderna's vaccine for emergency use in the United States, Canada, and the European Union.<blockquote>该公司十年来对mRNA背后的基础科学进行了反复研究，证明对其在创纪录的时间内成功开发出冠状病毒疫苗具有重要意义。2020年1月11日，中国科学家揭示了新型冠状病毒的基因序列。到2020年2月24日，Moderna向NIAID运送了第一剂mRNA冠状病毒疫苗，开始I期试验。2020 年 12 月，III 期试验证明对有症状的 COVID-19 有效率为 94.1%。FDA随后批准Moderna的疫苗在美国、加拿大和欧盟紧急使用。</blockquote> Moderna's COVID-19 vaccine marks its first — and only — commercially available product. On the back of strong demand for the vaccine, the company recorded its first-everprofitable quarterin Q1.<blockquote>Moderna 的 COVID-19 疫苗标志着其第一个也是唯一一个商业化产品。在疫苗需求强劲的推动下，该公司在第一季度录得了有史以来第一个盈利的季度。</blockquote> The company currently has 23 othervaccines and therapeuticsin its pipeline, including vaccines for the flu, HIV, and Cytomegalovirus (CMV), which causes birth defects in newborns, all using the same mRNA technology that has seen validation from the rollout of the COVID-19 vaccine.<blockquote>该公司目前在其产品线上还有 23 种其他疫苗和疗法，包括流感、艾滋病毒和导致新生儿出生缺陷的巨细胞病毒 (CMV) 疫苗，所有这些疫苗都使用的 mRNA 技术已在 COVID-19 疫苗的推出中得到验证。</blockquote> \"I think depending on your long-term outlook of what this company could do and all of the pipeline drugs that theoretically could come about over the next 10 years, based on those prospects, it could and should be one of the largest biotech companies in the world,\" Yee said.<blockquote>“我认为，根据您对这家公司所能做的事情的长期展望以及理论上未来 10 年可能出现的所有管道药物，基于这些前景，它可以而且应该成为世界上最大的生物技术公司之一，”Yee 说。</blockquote> A bull market in biotech<blockquote>生物技术牛市</blockquote> The biotech industry has seen a phenomenal run-up in the last several years, and any pullbacks in the last six months should be viewed in that context, Yee also noted.<blockquote>Yee 还指出，生物技术行业在过去几年中出现了惊人的增长，过去六个月的任何回调都应该在这种背景下看待。</blockquote> \"It has been one of the biggest bull markets in biotech in the last three years,\" he said, citing high valuations as well as record numbers of financings, investment, and IPOs.<blockquote>“这是过去三年生物技术领域最大的牛市之一，”他说道，并列举了高估值以及创纪录数量的融资、投资和 IPO。</blockquote> Going forward, Yee expects more M&amp;A activity. \"Some of the large companies which are more mature, I think, are having some struggles. And the way they've solved that is often by buying smaller companies,\" he said. \"In the big picture, things have still been very good for biotech.\"<blockquote>展望未来，Yee 预计会有更多并购活动。“我认为，一些比较成熟的大公司正在经历一些挣扎。他们解决这个问题的方法通常是收购规模较小的公司，”他说。“从大局来看，生物技术的情况仍然非常好。”</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock 'has taken on a life of its own' ahead of S&P 500 entrance<blockquote>Moderna 股票在标普500上市之前“有了自己的生命”</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock 'has taken on a life of its own' ahead of S&P 500 entrance<blockquote>Moderna 股票在标普500上市之前“有了自己的生命”</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nfinance.yahoo2021-07-21 09:31\n\n</h4>\n</header>\n<article>\nModerna (MRNA) is set to join the S&amp;P 500 index on Wednesday, replacing Alexion Pharmaceuticals Inc. (ALXN). The stock hassoaredamid the pandemic after its vaccine became instrumental in the fight against coronavirus.<blockquote>Moderna (MRNA) 将于周三加入标普500指数，取代 Alexion Pharmaceuticals Inc. (ALXN)。在其疫苗在抗击冠状病毒方面发挥作用后，该股在疫情大流行。</blockquote> Moderna stock has “taken on a life of its own,” Michael Yee, Managing Director and Senior Research Analyst at Jefferies, told Yahoo Finance (video above). “It's priced in a huge amount of assumptions over the next ten years that haven't played out yet. People believe it’s the Tesla of biotech.”<blockquote>杰富瑞（Jefferies）董事总经理兼高级研究分析师迈克尔-易（Michael Yee）告诉雅虎财经（上图视频），Moderna 的股票 “有了自己的生命”。“未来十年，它被大量的假设所定价，但这些假设尚未实现。人们认为这是生物技术的特斯拉”。</blockquote> That the biotech firm would be so well-recognized and valued at over $113 billion was no sure bet. For those who invested early in the company, that wager paid off.<blockquote>这家生物技术公司会如此广为人知，估值超过 1130 亿美元，这并不是一个确定的赌注。对于那些早期投资该公司的人来说，这一赌注得到了回报。</blockquote> \"Think about how fast they came up with nothing a year ago, and all of a sudden, they're doing $21 billion and have injected hundreds and hundreds and hundreds of millions of people with their drug safely,\" Yee said. \"That's a pretty big accomplishment.\"<blockquote>“想想一年前他们一无所获的速度有多快，突然之间，他们赚了 210 亿美元，并安全地为数亿人注射了药物，”易说。“这是一个相当大的成就。”</blockquote> <img src=\"https://static.tigerbbs.com/bb60075c3a90de67d77af15634fd41fa\" tg-width=\"858\" tg-height=\"588\" referrerpolicy=\"no-referrer\"><blockquote></blockquote> Moderna's rise to recognition<blockquote>Moderna的崛起</blockquote> The Cambridge, Massachusetts-based biotech company was founded in 2010 and spent its first two years instealth modedeveloping drugs using messenger RNA (mRNA).<blockquote>这家总部位于马萨诸塞州剑桥的生物技术公司成立于 2010 年，前两年一直在使用信使 RNA (mRNA) 开发药物。</blockquote> The promise of mRNA — what Moderna calls \"the software of life\" — in pharmaceuticals has been huge. Modified mRNA teaches cells how to produce the proteins needed to fight and prevent infection. By altering the four letters in an mRNA sequence, this new class of drugs can, in theory, target a wide range of illnesses. The mRNA platform also promises to accelerate the time it takes to select, develop, and manufacture vaccines.<blockquote>mRNA——现代评级公司的“生命软件”——在制药领域的前景是巨大的。修饰的mRNA教会细胞如何产生对抗和预防感染所需的蛋白质。通过改变mRNA序列中的四个字母，这类新药理论上可以针对多种疾病。mRNA平台还有望加快选择、开发和制造疫苗所需的时间。</blockquote> On these high expectations, Moderna achieved a billion-dollar valuation within two years. Initially, the company focused its efforts on treatments for cancer, cardiovascular issues, and some rare diseases. However, developers were embattled with the problem of delivering mRNA to cells — too-strong doses set the body's immune system against the drug while too-weak doses proved ineffectual in fighting disease.<blockquote>在这些高期望下，Moderna在两年内实现了10亿美元的估值。最初，该公司将精力集中在癌症、心血管问题和一些罕见疾病的治疗上。然而，开发人员被将mRNA输送到细胞的问题所困扰——太强的剂量会使身体的免疫系统抵抗药物，而太弱的剂量被证明在对抗疾病方面无效。</blockquote> Over time, the company shifted to pursuing vaccines, which CEO Stéphane Bancel believed would demonstrate the viability of the technology. Moderna had nine vaccines that made it to clinical trials, although none achieved liftoff.<blockquote>随着时间的推移，该公司转向追求疫苗，首席执行官 Stéphane Bancel 认为这将证明该技术的可行性。Moderna 有九种疫苗进入临床试验，但没有一种成功。</blockquote> That changed when a deadly global pandemic hit, kicking off a vaccine race in the U.S. between Moderna and pharmaceutical titans like Pfizer (who also developed an mRNA vaccine in partnership with BioNTech) and Johnson &amp; Johnson.<blockquote>当致命的全球大流行袭击时，这种情况发生了变化，在美国引发了 Moderna 与辉瑞（辉瑞还与 BioNTech 合作开发了 mRNA 疫苗）和强生公司等制药巨头之间的疫苗竞赛。</blockquote> The company's decade of research iterating on the basic science behind mRNA proved consequential in its success in developing a coronavirus vaccine in record time. On January 11, 2020, Chinese scientists revealed the genetic sequence for SARS-CoV-2. By February 24, 2020, Moderna shipped thefirst dosesof its mRNA coronavirus vaccine to the NIAID to begin phase I trials. And in December of 2020, phase III trials demonstrated 94.1% efficacy against symptomatic COVID-19. The FDA subsequently approved Moderna's vaccine for emergency use in the United States, Canada, and the European Union.<blockquote>该公司十年来对mRNA背后的基础科学进行了反复研究，证明对其在创纪录的时间内成功开发出冠状病毒疫苗具有重要意义。2020年1月11日，中国科学家揭示了新型冠状病毒的基因序列。到2020年2月24日，Moderna向NIAID运送了第一剂mRNA冠状病毒疫苗，开始I期试验。2020 年 12 月，III 期试验证明对有症状的 COVID-19 有效率为 94.1%。FDA随后批准Moderna的疫苗在美国、加拿大和欧盟紧急使用。</blockquote> Moderna's COVID-19 vaccine marks its first — and only — commercially available product. On the back of strong demand for the vaccine, the company recorded its first-everprofitable quarterin Q1.<blockquote>Moderna 的 COVID-19 疫苗标志着其第一个也是唯一一个商业化产品。在疫苗需求强劲的推动下，该公司在第一季度录得了有史以来第一个盈利的季度。</blockquote> The company currently has 23 othervaccines and therapeuticsin its pipeline, including vaccines for the flu, HIV, and Cytomegalovirus (CMV), which causes birth defects in newborns, all using the same mRNA technology that has seen validation from the rollout of the COVID-19 vaccine.<blockquote>该公司目前在其产品线上还有 23 种其他疫苗和疗法，包括流感、艾滋病毒和导致新生儿出生缺陷的巨细胞病毒 (CMV) 疫苗，所有这些疫苗都使用的 mRNA 技术已在 COVID-19 疫苗的推出中得到验证。</blockquote> \"I think depending on your long-term outlook of what this company could do and all of the pipeline drugs that theoretically could come about over the next 10 years, based on those prospects, it could and should be one of the largest biotech companies in the world,\" Yee said.<blockquote>“我认为，根据您对这家公司所能做的事情的长期展望以及理论上未来 10 年可能出现的所有管道药物，基于这些前景，它可以而且应该成为世界上最大的生物技术公司之一，”Yee 说。</blockquote> A bull market in biotech<blockquote>生物技术牛市</blockquote> The biotech industry has seen a phenomenal run-up in the last several years, and any pullbacks in the last six months should be viewed in that context, Yee also noted.<blockquote>Yee 还指出，生物技术行业在过去几年中出现了惊人的增长，过去六个月的任何回调都应该在这种背景下看待。</blockquote> \"It has been one of the biggest bull markets in biotech in the last three years,\" he said, citing high valuations as well as record numbers of financings, investment, and IPOs.<blockquote>“这是过去三年生物技术领域最大的牛市之一，”他说道，并列举了高估值以及创纪录数量的融资、投资和 IPO。</blockquote> Going forward, Yee expects more M&amp;A activity. \"Some of the large companies which are more mature, I think, are having some struggles. And the way they've solved that is often by buying smaller companies,\" he said. \"In the big picture, things have still been very good for biotech.\"<blockquote>展望未来，Yee 预计会有更多并购活动。“我认为，一些比较成熟的大公司正在经历一些挣扎。他们解决这个问题的方法通常是收购规模较小的公司，”他说。“从大局来看，生物技术的情况仍然非常好。”</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/moderna-stock-sp-500-134049499.html\">finance.yahoo</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","ALXN":"亚力兄制药"},"source_url":"https://finance.yahoo.com/news/moderna-stock-sp-500-134049499.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120529749","content_text":"Moderna (MRNA) is set to join the S&P 500 index on Wednesday, replacing Alexion Pharmaceuticals Inc. (ALXN). The stock hassoaredamid the pandemic after its vaccine became instrumental in the fight against coronavirus.\nModerna stock has “taken on a life of its own,” Michael Yee, Managing Director and Senior Research Analyst at Jefferies, told Yahoo Finance (video above). “It's priced in a huge amount of assumptions over the next ten years that haven't played out yet. People believe it’s the Tesla of biotech.”\nThat the biotech firm would be so well-recognized and valued at over $113 billion was no sure bet. For those who invested early in the company, that wager paid off.\n\"Think about how fast they came up with nothing a year ago, and all of a sudden, they're doing $21 billion and have injected hundreds and hundreds and hundreds of millions of people with their drug safely,\" Yee said. \"That's a pretty big accomplishment.\"\n\nModerna's rise to recognition\nThe Cambridge, Massachusetts-based biotech company was founded in 2010 and spent its first two years instealth modedeveloping drugs using messenger RNA (mRNA).\nThe promise of mRNA — what Moderna calls \"the software of life\" — in pharmaceuticals has been huge. Modified mRNA teaches cells how to produce the proteins needed to fight and prevent infection. By altering the four letters in an mRNA sequence, this new class of drugs can, in theory, target a wide range of illnesses. The mRNA platform also promises to accelerate the time it takes to select, develop, and manufacture vaccines.\nOn these high expectations, Moderna achieved a billion-dollar valuation within two years. Initially, the company focused its efforts on treatments for cancer, cardiovascular issues, and some rare diseases. However, developers were embattled with the problem of delivering mRNA to cells — too-strong doses set the body's immune system against the drug while too-weak doses proved ineffectual in fighting disease.\nOver time, the company shifted to pursuing vaccines, which CEO Stéphane Bancel believed would demonstrate the viability of the technology. Moderna had nine vaccines that made it to clinical trials, although none achieved liftoff.\nThat changed when a deadly global pandemic hit, kicking off a vaccine race in the U.S. between Moderna and pharmaceutical titans like Pfizer (who also developed an mRNA vaccine in partnership with BioNTech) and Johnson & Johnson.\nThe company's decade of research iterating on the basic science behind mRNA proved consequential in its success in developing a coronavirus vaccine in record time. On January 11, 2020, Chinese scientists revealed the genetic sequence for SARS-CoV-2. By February 24, 2020, Moderna shipped thefirst dosesof its mRNA coronavirus vaccine to the NIAID to begin phase I trials. And in December of 2020, phase III trials demonstrated 94.1% efficacy against symptomatic COVID-19. The FDA subsequently approved Moderna's vaccine for emergency use in the United States, Canada, and the European Union.\nModerna's COVID-19 vaccine marks its first — and only — commercially available product. On the back of strong demand for the vaccine, the company recorded its first-everprofitable quarterin Q1.\nThe company currently has 23 othervaccines and therapeuticsin its pipeline, including vaccines for the flu, HIV, and Cytomegalovirus (CMV), which causes birth defects in newborns, all using the same mRNA technology that has seen validation from the rollout of the COVID-19 vaccine.\n\"I think depending on your long-term outlook of what this company could do and all of the pipeline drugs that theoretically could come about over the next 10 years, based on those prospects, it could and should be one of the largest biotech companies in the world,\" Yee said.\nA bull market in biotech\nThe biotech industry has seen a phenomenal run-up in the last several years, and any pullbacks in the last six months should be viewed in that context, Yee also noted.\n\"It has been one of the biggest bull markets in biotech in the last three years,\" he said, citing high valuations as well as record numbers of financings, investment, and IPOs.\nGoing forward, Yee expects more M&A activity. \"Some of the large companies which are more mature, I think, are having some struggles. And the way they've solved that is often by buying smaller companies,\" he said. \"In the big picture, things have still been very good for biotech.\"","news_type":1,"symbols_score_info":{"ALXN":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":4340,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/178413148"}